A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts

作者：Brown H K^*; Ottewell P D; Evans C A; Coleman R E; Holen I

来源：Journal of Bone Oncology, 2012, 1(2): 47-56.

DOI：10.1016/j.jbo.2012.05.001

• Bone metastasis
• Breast cancer
• Bisphosphonate
• Combination therapy

We have previously shown that repeated sequential administration of doxorubicin, followed 24 h later by zoledronic acid, inhibits tumour growth in models of established breast cancer bone metastasis. As breast cancer patients only receive zoledronic acid every 3-4 weeks, the aim of the current study was to establish the anti-tumour and bone effects of a single administration of doxorubicin/zoledronic acid combination therapy in a bone metastasis model. %26lt;br%26gt;MDA-MB-231-GFP cells were injected i.e. in 6-week-old nude mice. On day 2, animals received PBS, doxorubicin (2 mg/kg i.v.), zoledronic acid (100 mu g/kg s.c.) or doxorubicin followed 24 h later by zoledronic acid. Anti-tumour effects were assessed on days 15/23 by quantification of apoptotic and proliferating cells and changes in expression of genes implicated in apoptosis, proliferation and bone turnover. Bone effects were assessed by mu CT analysis, bone histomorphometry and measurement of serum markers. A tumour-free control group was included. %26lt;br%26gt;Combination treatment reduced bone tumour burden compared to single agent or PBS control and increased levels of tumour cell apoptosis on day 15, but this was no longer detectable on day 23. Animals receiving zoledronic acid had increased bone density, without evidence of tumour-induced lesions. Bone histomorphometry showed that zoledronic acid caused a decrease in osteoblast and osteoclast numbers and an increase in osteoclast size, in both tumour-free and tumour-bearing animals. %26lt;br%26gt;Our data show that although zoledronic acid modifies the bone microenvironment through effects on both osteoblasts and osteoclasts, this does not result in a significant anti-tumour effect in the absence of doxorubicin.

• 出版日期2012-9